Citigroup’s Aspire Biopharma ASBP Stock Holding History

Citigroup’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-62	Closed	-$1.9K	–	6381
2026 Q1	$1.9K	Buy	+62	New	+$3.3K	﹤0.01%	5432
2023 Q2	–	Sell	-74	Closed	-$935K	–	5758
2023 Q1	$935K	Sell	74 -10	-12%	-$125K	﹤0.01%	2613
2022 Q4	$1.03M	Sell	84 -23	-21%	-$282K	﹤0.01%	2584
2022 Q3	$1.3M	Buy	107 +84	+365%	+$1.01M	﹤0.01%	2497
2022 Q2	$278K	Buy	+23	New	+$275K	﹤0.01%	3648

Other funds holding ASBP

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Crewe Advisors Salt Lake City, Utah $1.38B AUM 41.76% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

VWM

Valley Wealth Managers Paramus, New Jersey $1.73B AUM 42.12% 1-Year Est. Return

Crossingbridge Advisors Pleasantville, New York $567M AUM 0.34% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citigroup's ASBP Position: Q2 2026 in Review

Citigroup sold out of Aspire Biopharma (ASBP) in Q2 2026, closing a stake of 62 shares — an estimated $1.9K sold.

Citigroup first reported a position in ASBP in Q2 2022 and held it in 5 quarters. The position peaked at $1.3M in Q3 2022. 13 funds tracked by Wall St. Rank hold ASBP as of Q2 2026.

Citigroup reported no remaining Aspire Biopharma position as of Q2 2026 after selling out during the quarter.
Citigroup sold 62 Aspire Biopharma shares in Q2 2026, an estimated $1.9K.
Citigroup first reported a position in Aspire Biopharma in Q2 2022 and held it in 5 quarters.
Citigroup's Aspire Biopharma position peaked at $1.3M in Q3 2022.
13 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.